Please assess the completion status of the following clinical trial:

Trial Title: Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCT

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must have one of the following disease categories:~  * Acute myeloid leukemia (AML) beyond 2nd remission or relapsed/refractory disease~ * Acute lymphoblastic leukemia (ALL) beyond 2nd remission or relapsed/refractory disease~ * Chronic myeloid leukemia (CML) beyond 2nd chronic phase or in blast crises~ * Myelodysplastic syndrome (MDS)~ * Myeloproliferative disorders including myeloid metaplasia and myelofibrosis~ * High risk non-Hodgkin's lymphoma (NHL) in first remission~ * Relapsed or refractory NHL~ * Hodgkin's lymphoma (HL) beyond first remission~* Performance status by Karnofsky of \>= 70% or Lansky \> 70% for patients \< 16 years of age~* Human leukocyte antigen (HLA) mismatched related or unrelated donor identified 8/10 or 9/10~* Willingness to take oral medications during the transplantation period~* Willingness and ability to sign a written informed consent (assent if applicable)~Exclusion Criteria:~* Prior myeloablative allogeneic or autologous HSCT~* Human immunodeficiency virus (HIV) infection~* Pregnant or lactating females~* Evidence of uncontrolled active infection~* Down syndrome~* Serum creatinine (CR) \< 1.5mg/dl or 24 hour CR clearance \< 50 ml/min~* Direct bilirubin \> 2 x upper limit of normal (ULN)~* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \> 2 x ULN~* Carbon monoxide diffusing capability test (DLCO) \> 60% predicted and in children- room air oxygen saturation \> 92%~* Left ventricular ejection fraction \< 45% and in children-shortening fraction \< 26%~* Fasting cholesterol \> 300 mg/dl or triglycerides \> 300 while on lipid lowering agents~* Patients who have received an investigational drug within 30 days of enrollment in study~* Patients with prior malignancies except basal cell carcinoma or treated carcinoma in-situ; cancer treated with curative intent \> 5 years will be allowed; cancer treatment with curative intent =\< 5 years will not be allowed

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 30 Years
- Healthy Volunteers: f

Study Arms:
- Treatment (sirolimus, HSCT, MMF) (Type: EXPERIMENTAL): Patients receive sirolimus PO starting on day -3, 3 times a week during hospitalization and then once a week for up to 6 months. Patients undergo HSCT on day 0. Patients also receive mycophenolate mofetil IV or PO TID on days 1-180. Treatment continues in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).